Madrigal Pharmaceuticals price target raised to $475 from $400 at Oppenheimer

Oppenheimer raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $475 from $400 and keeps an Outperform rating on the shares following quarterly results. The firm sees the new data in the F4c population, together with implications from the recent Phase 2 SYMMETRY results for EFX, as derisking the MAESTRO-NASH OUTCOMES study that remains on track to readout in 2027. With this promising update, Oppenheimer increases its probability of success for the F4 population.